Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953548 · ClinicalTrials.gov registry record · Phase 3
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT02953548 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT02953548, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase, and an open-label extension phase. The pilot phase only will be described in this record. 2 cohorts of 5 participants will be enrolled sequentially. All participants will receive GWP42003-P.
Interventions
- DRUG GWP42003-P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2018-05-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953548
The ClinicalTrials.gov registry entry for NCT02953548 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GWP42003-P is the first listed.
NCT02953548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02953548 about?
NCT02953548 is a clinical study titled "Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)". This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase, and an open-label extension phase. The pilot phase only will be described in this record. 2 cohorts of 5 participants will be enrolled sequentially. All participants will receive GWP42003-P.
What is the current status of trial NCT02953548?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2017-04-24. Estimated completion is 2018-05-07.
What interventions are being tested in trial NCT02953548?
The interventions under investigation include: GWP42003-P (DRUG).
Who is sponsoring clinical trial NCT02953548?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.